MedPath

Safety Study of F2695 SR in Major Depressive Disorder

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: F2695 SR
Registration Number
NCT01034267
Lead Sponsor
Forest Laboratories
Brief Summary

The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
828
Inclusion Criteria
  • Completed 1 of the lead-in studies LVM-MD-01, LVM-MD-02, or LVM-MD-03
  • Have normal examination findings at the final visit of the lead-in study
  • Have a negative serum pregnancy test at the final visit of the lead-in study if a woman of child-bearing potential
Exclusion Criteria
  • Any exclusionary psychiatric or medical condition that developed during the lead in study
  • Patients considered a suicide risk
  • Women who are pregnant, breastfeeding, or planning to become during the study OR are sexually active and not currently using a medically acceptable method of contraception

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1F2695 SR(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
Primary Outcome Measures
NameTimeMethod
Adverse events, clinical laboratory tests, vital sign measurements, electrocardiograms, physical examinations, Columbia-Suicide Severity Rating Scale48 weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (68)

Forest Investigative Site 55

πŸ‡ΊπŸ‡Έ

Dothan, Alabama, United States

Forest Investigative Site 29

πŸ‡ΊπŸ‡Έ

Scottsdale, Arizona, United States

Forest Investigative Site 31

πŸ‡ΊπŸ‡Έ

Beverly Hills, California, United States

Forest Investigative Site 3

πŸ‡ΊπŸ‡Έ

Costa Mesa, California, United States

Forest Investigative Site 12

πŸ‡ΊπŸ‡Έ

Encino, California, United States

Forest Investigative Site 6

πŸ‡ΊπŸ‡Έ

Escondido, California, United States

Forest Investigative Site 22

πŸ‡ΊπŸ‡Έ

Oceanside, California, United States

Forest Investigative Site 38

πŸ‡ΊπŸ‡Έ

Sherman Oaks, California, United States

Forest Investigative Site 36

πŸ‡ΊπŸ‡Έ

Denver, Colorado, United States

Forest Investigative Site 28

πŸ‡ΊπŸ‡Έ

Denver, Colorado, United States

Scroll for more (58 remaining)
Forest Investigative Site 55
πŸ‡ΊπŸ‡ΈDothan, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.